Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors lsc-webmaster Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors Read More »
VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects lsc-webmaster VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects Read More »
VCN-01 is an encouraging therapy against retinoblastoma lsc-webmaster VCN-01 is an encouraging therapy against retinoblastoma Read More »
Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11 lsc-webmaster Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11 Read More »
Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial lsc-webmaster Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial Read More »
Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolyticadenovirus VCN-01 lsc-webmaster Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolyticadenovirus VCN-01 Read More »
Characterization of Clostridium difficile isolates collected during a phase 2b clinical study with SYN-004 (ribaxamase) for the prevention of C. difficile infection lsc-webmaster Characterization of Clostridium difficile isolates collected during a phase 2b clinical study with SYN-004 (ribaxamase) for the prevention of C. difficile infection Read More »
Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies lsc-webmaster Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies Read More »